The CARE Technology Lanka (Pvt) Ltd of The Institute for Combinatorial Advanced Research and Education of KDU (KDU-CARE) entered into a research service agreement with Interpharm (Pvt) Ltd, on the 25th November 2022, to conduct the Bioequivalence (BE) study of Gliclazide MR 60 mg manufactured by the Gamma Interpharm (Pvt) Ltd. . Major General Milinda Peiris, the Vice-Chancellor, Prof. Thushara Weerawardane, Director/ KDU-CARE/Managing Director CTL, Institute of Combinatorial Advanced Research and Education (KDU-CARE), signed the agreement on behalf of General Sir John Kotelawala Defence University. Mr. Kalana Hewamallika, Chairman/Managing Director, and of Mrs. S. L. Sivayogarajan –Director of operations of Gamma Interpharm (Pvt) Ltd., signed the agreement on behalf of Gamma Interpharm (Pvt) Ltd. C. A. Munisinghe – General Manager (Quality Assurance), D.R.P. Perera -General Manager (Production) represented the Gamma Interpharm (Pvt) Ltd. on this occasion., Snr. Prof Rohini Fernandopulle – WHO National Consultant on Regulatory Functions to N MRA, Prof. Charitha Gunasekara – Former Acting Director, KDU-CARE, Dr. Himali Jayasinghearachchi, Principal Investigator-Analytical, Dr. Nadeesha Ratwadu-Co-Investigator- Analytical, and Dr Pandula Athauda-arachchi,-Principle Investigator (Clinical)/Consultant Interventional Cardiologist (UK & SL Board Certified) and Clinical investors of the project Dr. Janaka Munasinghe, Dr. Priyamali Jayesekara, Dr. Dumitha Govindapala -Consultant Physicians(University Hospital KDU)), also participated in this occasion.
In addition, The CARE Technology Lanka (Pvt) Ltd (CTL) of the Institute for Combinatorial Advanced Research and Education (KDU-CARE) of KDU has successfully completed the Bioequivalence (BE) study on Metformin extended-release for Gamma Interpharm (Pvt) Ltd. The final report was submitted by the Vice-Chancellor of KDU Major General Milinda Peiris to Mr. Kalana Hewamallika-Chairman/Managing Director of Gamma Interpharm (Pvt) Ltd.
